Here's some basics on the science - Leronlimab blocks the CCR5 receptor. The CCR5 receptor is one of the main receptors that binds proteins (ligands) that are responsible for immune response and inflammation. In diseases often over-activation of the immune system leads to either autoimmunity (an attack by the immune system on ones own cells), an out of control immune response that causes high levels of inflammation and the generalized destruction of cells or in the case of cancer a hi-jacking of the immune system that protects the tumor and increases the chance it will metastasis.

Leronlimab by blocking CCR5 lowers that over-active immune response while allowing the other receptors to carry on normal immune response. This curbs the immune systems negative role in the disease state. There are a very wide range of diseases affected by the CCR5 receptor as shown in the leronlimab disease list -

https://investorshangout.com/post/view?id=6297787

If you want to take a closer look at the science in a search engine type in the name of any of those diseases and CCR5. There are thousands of medical white papers on CCR5.

On the business side we had a bad CEO who hired an awful company to run our trials, which is why the stock price is crashed out. Happily our new CEO, Dr. Jay Lalezari has ran well over a hundred clinical trials and has worked with leronlimab since 2012. We are currently waiting for a trial for colorectal cancer to commence, a human study in Alzheimer's, a study for leronlimab as an HIV cure, a preclinical study in glioblastoma and a pre-clinical study in MASH.